Bristol-Myers Squibb Trading Volume Plummets to 160th Rank Amid Strategic Moves in Cancer Care

On June 17, 2025, Bristol-Myers Squibb (BMY) saw a significant drop in trading volume, with a total of $446 million in shares traded, marking a 38.76% decrease from the previous day. This decline placed BMY at the 160th position in terms of trading volume for the day. The stock has been on a downward trend, falling 2.98% over the past three days, with a cumulative decline of 6.87% during this period.

Bristol-Myers Squibb has recently expanded its presence in the cancer care sector through a strategic acquisition. On June 10, the company announced that its subsidiary, RayzeBio, would acquire Philochem AG for up to $1.35 billion. This move is part of Bristol-Myers Squibb's broader strategy to enhance its radiopharmaceutical capabilities and strengthen its position in the prostate cancer treatment market.

In addition to the acquisition of Philochem AG, Bristol-Myers Squibb has also entered into a partnership with BioNTech to develop a PD-L1/VEGF-A bispecific antibody. This collaboration involves an upfront payment of $1.5 billion and potential additional payments of up to $7.6 billion, further solidifying Bristol-Myers Squibb's commitment to advancing cancer therapies.